Peripheral Blood Biomarkers and Response to Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma
NCT07734857
·
clinicaltrials.gov ↗
NOT_YET_RECRUITING
Status
100
Enrollment
OTHER
Sponsor class
Conditions
Hepatocellular Carcinoma (HCC)
Interventions
OTHER:
No intervention (observational study)
Sponsor
Shanghai Zhongshan Hospital